Introduction: The Hematology and Oncology Department was established in 1994. First transplantation (Tx) was performed in 1991, but routinely since 1994. In the past 20 years, 735 allogeneic Tx and 1059 autologous Tx have been provided in the department. The number of alotransplantations has been stable in recent 10 years with a yearly average of around 41 as far as allogeneic Tx is concerned (35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53) and an average of 51 connected to autologous . There is an interesting, but very easily explicable phenomenon connected to individual diagnoses the representation of which has changed in allogeneic Tx. Materials (or patients) and methods: Retrospective analysis -internal database data dealing with a group of patients who were transplanted from 1994 to 2014. Results: In the course of the last 20 years, 735 allogeneic Tx have been provided in the Department of Hematology and Oncology of the Teaching Hospital in Pilsen. 424 patients were men and 311 women (1,3/1). In the first decade, the most common indication for the Tx was chronic myeloid leukemia (CML) (37%), followed by acute myeloid leukemia (AML) -22% of all transplants. The third most common diagnosis was acute lymphoblastic leukemia (ALL-11%) which was followed by chronic lymphocytic leukemia CLL (9%), MDS (5%), lymphomas (5%) and multiple myeloma (3%). In case of involvement of a very specific hematology therapy (tyrosine kinase inhibitors, another specific immunotherapy...), there was a rapid change in major indications for allogeneic Tx. However, in the second decade, CML-originally the main diagnosis -dropped to about 6th place (only 3% of all transplants) and remained an indication for Tx only in case of immunotherapy failure. During this period, the main diagnosis became AML (45%); the second most common diagnosis was ALL (13%) closely followed by CLL (12%). Lymphomas formed around 8% of all transplants, MDS about 6% and multiple myeloma remained on the same level (4% Introduction: Accurate data collection is essential for the validity in use of scientific data entered in databases (DB).
Hemato-oncology department, CHARLES UNIVERSITY HOSPITAL PILSEN, Pilsen, Czech Republic Introduction: The Hematology and Oncology Department was established in 1994. First transplantation (Tx) was performed in 1991, but routinely since 1994. In the past 20 years, 735 allogeneic Tx and 1059 autologous Tx have been provided in the department. The number of alotransplantations has been stable in recent 10 years with a yearly average of around 41 as far as allogeneic Tx is concerned (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) and an average of 51 connected to autologous . There is an interesting, but very easily explicable phenomenon connected to individual diagnoses the representation of which has changed in allogeneic Tx. Materials (or patients) and methods: Retrospective analysis -internal database data dealing with a group of patients who were transplanted from 1994 to 2014. Results: In the course of the last 20 years, 735 allogeneic Tx have been provided in the Department of Hematology and Oncology of the Teaching Hospital in Pilsen. 424 patients were men and 311 women (1,3/1). In the first decade, the most common indication for the Tx was chronic myeloid leukemia (CML) (37%), followed by acute myeloid leukemia (AML) -22% of all transplants. The third most common diagnosis was acute lymphoblastic leukemia (ALL-11%) which was followed by chronic lymphocytic leukemia CLL (9%), MDS (5%), lymphomas (5%) and multiple myeloma (3%). In case of involvement of a very specific hematology therapy (tyrosine kinase inhibitors, another specific immunotherapy...), there was a rapid change in major indications for allogeneic Tx. However, in the second decade, CML-originally the main diagnosis -dropped to about 6th place (only 3% of all transplants) and remained an indication for Tx only in case of immunotherapy failure. During this period, the main diagnosis became AML (45%); the second most common diagnosis was ALL (13%) closely followed by CLL (12%). Lymphomas formed around 8% of all transplants, MDS about 6% and multiple myeloma remained on the same level (4%). Conclusion: The Department of Hematology and Oncology of the Teaching hospital in Pilsen provided approximately 80 transplantations a year. Over the past 20 years, there has been a significant change in transplant strategy as far as the order of diagnosis is concerned. With the development of new drugs in hematology (specific immunotherapy, tyrosine kinase inhibitors and others), there has been a steep decrease in allogeneic transplantations in patients with CML; and acute leukemias are getting to the foreground now. Trend in Czech Republic closely reflected trends in Europe. Disclosure of Interest: None declared.
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Optimizing data collection at a BMT unit C. Introduction: Accurate data collection is essential for the validity in use of scientific data entered in databases (DB).
From an earlier study we identified the difficult task in entering accurate data to local and international databases. We therefore decided to examine which tools we have available to collect the data. We frequently participate in requests from CIBMTR, EBMT, local DB and we enter patients into clinical research protocols, all tasks where data collection is necessary. The patient file is in a paper and an electronic version. The paper version is documents which either haveń t been converted nor been able to convert into an electronic version. Within the patient paper file there is already a document to list essential data for data registering, and since the electronic patient file has been implemented, the awareness of paper documents has declined. Currently some data are collected solely by the data managers (DM) and extracted from patient files at the hospital and from national patient registries. Some data, however, must be reviewed and interpreted by a physician to in order to extract valid data. Therefore, it is necessary for the treating physician, to have an overview of which data is essential to list in the patient file. The BMT unit is preparing for JACIE accreditation and according to standard B9.1:'' The Clinical Program must furnish evidence of its own periodic data audits to determine if data are accurate for evaluation of patient outcomes'' e.g. outcome analysis on day þ 100, þ 180 and annually. Aim: To optimize data collection to increase validity of data entered to CIBMTR, EBMT, DB and CRFs. To identify which data are to be collected and entered in CIBMTR, EBMT, DB and Clinical Research Files (CRF) . To create an overview of which data to be collect to DB and CRFs to ease the data collection at patient visits. Materials (or patients) and methods: We reviewed forms from the CIBMTR, EBMT and CRFs from the clinical research team and listed which essential data are needed on day þ 100, þ 180 and annually. We identified and reviewed existing paper documents in the patient paper file, which previously has been created to give
S535
an overview of which data to be collected and also to enter data on by the treating physician. By looking into our electronic patient file system, we discovered the possibility to create standard notes. Results: The existing paper document is now changed to a schedule to give an overview of which data to be collected on day þ 100, þ 180 and annually. Introduction: Given the global nature of the work done by hematopoietic stem cell donor registries, a system to uniquely identify potential donors on a global scale is needed to facilitate communication and prevent errors in identification of donors. A standard machine-readable format for a Global Registry Identifier for Donors (GRID) that can be used by electronic process control systems, as well as a standard format for the human-readable version, is under development. Materials (or patients) and methods: WMDA has signed a Memorandum of Understanding with ICCBBA to assign and manage the register of registry identifiers and support the development of associated standards documents. Representatives from WMDA and ICCBBA have identified three phases for the project: Phase 1 -Registry identifier allocation rules, GRID format, GRID eye-readable presentation, and GRID data structure for electronic transfer are defined. Guidance for registries for mapping local identifiers to the GRID is developed. Phase 2 -EMDIS and BMDW databases and messaging standards support GRID. Use of GRID in communication between registries is recommended but not required. Phase 3 -GRID is a mandatory field in communication with EMDIS and BMDW databases and in communication between registries. GRID is used as the key donor identifier on search reports. GRID is used on product labels when a donor identifier is required. Results: Phase 1 of the project is in progress. The format for the GRID will be a 4-character (all numeric) registry identifier assigned by ICCBBA followed by a 15-character (numeric or uppercase alpha) donor identifier assigned by the registry for a total of 19 characters. In the human-readable form, the alphanumeric sequence will be divided into blocks of 4,4,4,4,3 to assist in manual transcription. Leading zeroes would be used for donor identifiers less than 15 characters. In the humanreadable form, a modulus 37-2 check character will be displayed. This can be used to ensure correct data entry should the number be entered into a computer system via a keyboard. In electronic communications, the characters &,3 will be used to identify the number as containing a Hematopoietic Stem Cell Registry GRID. Code 128 will be used if the GRID is to be represented in a linear bar code and Data Matrix will be used if the GRID is represented in a two-dimensional bar code.
Conclusion:
It is anticipated that implementation of a GRID following the 3-phase project plan will take 3-5 years. The GRID has been designed to allow registries to insert their current donor identifiers (alphanumeric characters only) into the GRID to facilitate the adoption of the new identifier. For example, a registry has been assigned the identifier 3054 and currently has assigned the identifier A12345 to a donor. The GRID would be 3054 0000 0000 0A12 345. It is believed that the GRID will improve electronic communication, traceability, and accuracy in identifying potential donors by standardizing systems across the globe. [1] has been developed through a broad collaboration of histocompatibility and immunogenetics clinicians, researchers, instrument manufacturers and software developers [2] . Using these principles, we have extended the XML based Histoimmunogenetic Markup Language (HML) [3] to include reporting of NGS-based genotyping of HLA and KIR. Materials (or patients) and methods: HML has been undergoing development to accommodate NGS based genotyping for the past year in an effort led by the National Marrow Donor Program through a series of meetings and discussions with the HLA Information Exchange Data Format Standards Group, as well as the Immunogenomic NGS Data Consortium, a community of registries, clinical and research laboratories, and industry partners focused on identifying and addressing specific data-reporting requirements for NGSbased genotyping. In Sep 2014, a Data Standards Hackathon (DaSH) was held to develop new ways to exchange NGS data for HLA and KIR. During this event MIRING was further refined, and new substantial requirements were identified for HML 1.0. Results: HML 1.0 retains similar overall structure to previous versions, but with notable changes. As before, reporting of primary data is separated from allele assignment. NGS is supported by new XML structures to capture all NGS data and metadata required to produce a genotyping result, including analysis-dependent (dynamic) and method-dependent (static) components. Pointers to external locations are used to refer to registered methodologies, raw NGS reads, and reference standards. A separate component describing consensus sequences and variants was created specifically to accommodate NGS data, but could be used for other methodologies if desired. This component includes metadata describing the sequences such as references sequences, phasing information, expected copy number, sequence block continuity, and other metadata. Reporting of allele assignment with full genotypic and allelic ambiguity is achieved through the use of GL Strings [5] .
Conclusion: HML 1.0 has been finalized and can be found on schemas.nmdp.org. Reporting of NGS based genotyping of HLA and KIR conforming to MIRING principles is possible using a combination of HML and semantic and syntactic validation tools. As NGS technologies become the de facto standard for HLA and KIR genotyping in both research and clinical settings, standards describing technical specifications for exchanging the genotyping results and the surrounding metadata become ever more important. We are working with healthcare standards organizations (e.g., HL7) to include these data and metadata described in HML 1.0 in clinical messages and structured documents. Materials (or patients) and methods: High quality HLA-A, -B, -C, -DRB1 and -DQB1 haplotype frequencies (HF) are the actual basics for matching predictions between patients and potential donors. This study highlights the impact of population specific HF on the match prognoses for donors from Southwest Asia, i.e. from the Middle East and Turkey (ASSW). The HF have been estimated from two subsets of the German donor pool: (1) all donors with molecular assignments at least for HLA-A and -B (ALL) (2) the subset of (1) explicitly assigned to ASSW origin. The matching predictions have been assessed using high resolution confirmatory typing results of donors without previously complete high resolution data. We used weighted linear regression as well as logarithmic score (u(x)) for the whole model and for the predictions up to 10% probability (u 10 (x)), i.e. the most difficult searches. This judgment has been applied to the 10/10 (full HLA match) and the 9/10 (1 HLA mismatch) predictions. Results: The unrestricted sample including 4.4 million donors yielded 134.000 HF compared to 25.000 HF for the 122.000 ASSW donors. Altogether 617 5-locus HLA high resolution typings for ASSW donors have been used for the validation. The goodness of fit (R 2 ) of the unrestricted 10/10 model is 0.95 compared to 0.98 of the ASSW model (figure 1). Logarithmic scores u(x) and u 10 (x) were 0.225 and 0.13 for all donors and 0.179 and 0.098 for ASSW donors. The picture for the 9/10 model is similar except that the R 2 is slightly higher. Conclusion: Despite the relatively small number of HLA types available for the validation, the importance of population specific HF for matching predictions could be underlined in this study. Unfortunately the application of the result of this and similar studies is severely hampered by two factors. First, the lack of adequate a-priori donor HLA types for every patient population which prevents the estimation of HF and, second, the absence of substantial numbers of a-posteriori donor high resolution HLA types for the validation of the estimated HF. Disclosure of Interest: None declared. Introduction: SR-cGVHD represents an unmet challenge in allogeneic transplantation. Although research has been very active,the lack of fully developed research methods made it difficult to conduct clinical trials suitable for drug regulatory approval,leading to absence of any FDA-approved medication for SR-cGVHD. To bridge this gap, in 2006 the NIH cGVHD Consensus Project provided recommendations (NIH-cGCP-R) for design of clinical trials. The uptake of NIH-cGCP-R in the recent literature and their impact on the quality of clinical research on SR-cGVHD, has not been yet evaluated. Materials (or patients) and methods: We aimed to identify recurrent methodological deviations from NIH-cGCP-R in the recent literature for SR-cGVHD; to ascertain if these deviations introduced systematic biases; to evaluate whether a significant methodological improvement over time could be observed,as a possible consequence of the NIH-cGCP-R. Search in Medline for non-randomized studies (ST) published between 1998 and 2013 for systemic treatment of SR-cGVHD yielded 2901 hits:152 were pertinent to our topic,related to 51 interventions(INT).We excluded 42 ST with less than 3 subjects and 28 ST whose INT had less than 3 published reports in the analyzed timeframe; 82 ST related to 9 INT (Extracorporeal photopheresis, Rituximab, Mycophenolate, Imatinib, Mesenchymal Stem Cells, Methotrexate, Pentostatin, Sirolimus, Thalidomide) were further analyzed.We generated a 61-items checklist from (1) to evaluate adherence to NIH-cGCP-R. Four investigators applied the checklist and extracted efficacy and toxicity data from all the 82 ST, with high concordance. Chisquare or Fisher's exact test were used to compare items adherence across cut-off dates.Meta-analysis was performed to measure the pooled effect size for global response rate (GRR) and meta-regression analyses were employed to study the effect of covariates on GRR. Results: The NIH-cGCP-REC had a modest impact on the methodologic pattern of the ST over time, without overall significant changes before and after the arbitrary cut-off date of Jan 1,2008. Moving the cut-off date for each year from 2006 to 2013 did not change the results. Better adherence to NIH-cGCP-R in the critical subset of GRR determination (GRR-DET) was significantly associated with a lower GRR of the evaluated INT. This subset included:use of calendar-driven data collection and objective measures to define response,the requisite of a magnitude of change for partial response,specification of a pre-defined timing for response evaluation and reporting a measure of response duration. Adherence to NIH-cGCP-R in the GRR-DET subset was significantly higher after 2008. Conclusion: An overestimation bias is evident in the reported GRR of recent SR-cGVHD ST: it is thus likely that exaggeration of treatment effects led to accumulation of an array of compounds of unknown true efficacy,thereby contributing to a jammed drug development. The global uptake of NIH-cGCP-R in the recent literature was limited; however it was significant in improving the methodology of response determination,thereby reducing overestimation bias. Although a minor change,this may have a strong impact in lowering false expectations about new INT tested,thus avoiding that further patients are subjected to ineffective treatments. Family Medicine and Public Health, Sultan Qaboos University Hospital, Muscat, Oman Introduction: Comparison to historical controls when concurrent controls are not available remains a common strategy for retrospective comparative studies. Nevertheless, the probability of censoring is different between the current and the historical cohorts. We hypothesized that this informed censoring will bias the survival probability estimate to favor the cohort with shorter follow up time. Materials (or patients) and methods: We simulated a cohort of 500 patients using Weibull distribution with 50% probability of failure and a maximum follow up time of 5 units. We then derived the second cohort where the maximum follow up time was set to be 50% of the original cohort. Failure events that occurred beyond the maximum follow up of 2.5 units in the first cohort were changed to censored events in the second cohort. Kaplan-Meier survival probability was estimated at 1 and 2 units follow up time for both cohorts. Results: The total number of failure events in first and second cohorts were 242 and 98 respectively. The 1 and 2 year survival probabilities were 94% and 85% for the first cohort and 94% and 85% for the second cohorts with overlapping Kaplan-Meier survival curves indicating no bias in the survival probability estimates. Conclusion: Survival analysis is robust to informed censoring in studies comparing current outcomes to historical controls. The results should be validated utilizing data from prospectively collected datasets in the field of malignant hematology and bone marrow transplantation. Disclosure of Interest: None declared. Materials (or patients) and methods: Supervised machine learning predictive models such as GBM, SVM and ANN were compared to Logistic Regression (LR) in predicting day-100 Treatment Related Mortality (TRM). Models were trained using 70% of the dataset while 30% of the data was kept for the validation purpose. Predictive ability of the model was assessed using Area Under the receiver operating characteristic curve (AUC). AUC was obtained to measure the in-sample fit and out-sample fit using training and validating data set respectively. Five-fold cross validation was used to avoid model over fitting and ensure model stability. Decision matrix was used in order to adjust for TRM non-proportionality using prior probabilities and appropriate decision consequences. Average profit summary statistics was computed to assess model performance. Introduction: In stochastic modelling of biochemical systems enables us to explain the random feature in biological processes such as transcription and translation when exact numbers of molecules in reactions are known. In this study, we model a realistically complex MAPK/ERK (mitogen activated kinase/extracellular signal reglated kinase) pathway via stochastic approaches, estimate its reaction rate contants and evaluate the results biologically in details. MAPK/ERK is one of the main signalling pathways regulating the growth control in eucaryotic cells and involves many genes whose major components are Ras, Raf, MEK and ERK proteins. Also due to its importance in cell production, differention and apopthosis, it has been studied intensivly in oncogene researches. Here, we apply a western blotting dataset which has measurements for 5 proteins at 8 time points. Under such very sparse data, we apply a quasi list of reactions which describes the system by the EGFR degradation and the RKIP protein besides the MEK protein in the regulation of the system. Materials (or patients) and methods: In modelling, we perform the Euler-Maruyama approximation, which is presented by the following expression.
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where DY t denotes the change in state at time t, m and b show the mean and the variance terms, respectively, that are dependent on Y and reaction rates Y. Finally DW t indicates the independent and identically distributed Brownian vector at time t. Accordingly, in order to infer Y for partially observed data, we implement the particle filtering approach within the Bayesian framework. This method enables us to estimate both missing observations and Y by decreasing the high correlational structure in calculations, resulting in more accurate results in inference. In the computation, we use western blotting data whose proteins are harvested via the pull-down method for the COS cells. Also we equate measured optical intenties to a fixed number of molecules and take the rest of them proportionally on that value in order to convert the available data into a suitable structure for statistical analyses. Finally observations are assumed to have no measurement error, meaning that their uncertainies are only caused by stochasticity of protein interactions. Results: From findings, we detect that the estimated structure of the system validates the biological knowledge such that the EGF degradation is crucial and the RKIP gene has a significant role in the activation of this pathway. Moreover as we get estimates of the reaction rates, we interpret the importance of each reaction such as we can evaluate the speed of the production of the target gene c-Fos in the nucleus. Conclusion: We observe that the suggested methods to infer the MAPK/ERK pathway are successful in the construction of the system under very sparse data and enable us to critically assess each reaction in the pathway by interpreting it biologically in details. These methods, additionally, can be used for any other complex systems. On the other side, the high correlation between genes causes high computational demand. To improve the underlying cost, we consider to use the inhomogenous poisson process whose model parameters can be inferred by a mixture of the Gibbs sampling approach with other Bayesian techniques. [P768]
